Cochrane Database of Systematic Reviews 2012
DOI: 10.1002/14651858.cd005262.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Pentoxifylline for intermittent claudication

Abstract: BackgroundIntermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating individuals with PAD, but results of these studies are variable. This is an update of a review first publishe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
29
0
1

Year Published

2012
2012
2021
2021

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 62 publications
(30 citation statements)
references
References 69 publications
0
29
0
1
Order By: Relevance
“…The overall data supporting any functional benefit for treatment of patients with PAD with pentoxifylline are weak. 68,69 The limited benefit of naftidrofuryl in patients with PAD also cannot be linked to any welldefined mechanism of action. [69][70][71] Exercise training has been a mainstay of treatment for PAD, with a well-established benefit during a typical 12-week training program.…”
Section: Existing Medical Therapy For the Exercise Limitation In Padmentioning
confidence: 99%
“…The overall data supporting any functional benefit for treatment of patients with PAD with pentoxifylline are weak. 68,69 The limited benefit of naftidrofuryl in patients with PAD also cannot be linked to any welldefined mechanism of action. [69][70][71] Exercise training has been a mainstay of treatment for PAD, with a well-established benefit during a typical 12-week training program.…”
Section: Existing Medical Therapy For the Exercise Limitation In Padmentioning
confidence: 99%
“…The difference in percentage improvement in pain-free walking distance and total walking distance ranged from À33.8 % to 73.9 % and 1.2 % to 155.9 %, respectively. Additionally, there was no effect on ABIs (Salhiyyah et al 2012). As such, pentoxifylline is currently considered a second-line alternative therapy to cilostazol to improve walking distance in patients with intermittent claudication (Anderson et al 2013).…”
Section: Pentoxifyllinementioning
confidence: 87%
“…Pentoxifylline is a compound that decreases blood viscosity, improves erythrocyte flexibility, and increases microcirculatory flow and tissue oxygenation (Salhiyyah et al 2012). Although pentoxifylline is generally well tolerated, a recent review of the 23 randomized-control trials comparing pentoxifylline to placebo demonstrated a great deal of heterogeneity with regard to the agent's effect on pain-free walking distance and total walking distance.…”
Section: Pentoxifyllinementioning
confidence: 99%
“…Therefore, vasoactive agents, such as Ginkgo biloba extract, dextran, and pentoxifylline, have been used with an aim to gain more blood flow in the cochlea [10,11] . Pentoxifylline has been reported to have an ability of increasing erythrocyte flexibility, reducing blood viscosity, and increasing microcirculatory flow [12,13] . DM can cause microvascular injuries and other microcirculatory disorders including unexpected increment of blood viscosity and thrombotic and embolic events [14] .…”
Section: Introductionmentioning
confidence: 99%